Standard BioTools Inc. (NASDAQ:LAB) Position Decreased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 19.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 306,871 shares of the company’s stock after selling 75,617 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.08% of Standard BioTools worth $592,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Xponance Inc. bought a new stake in Standard BioTools during the second quarter worth approximately $34,000. Nisa Investment Advisors LLC boosted its stake in shares of Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock worth $35,000 after acquiring an additional 14,732 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in shares of Standard BioTools in the 2nd quarter worth $39,000. Creative Planning acquired a new stake in shares of Standard BioTools during the third quarter worth $39,000. Finally, Algert Global LLC acquired a new stake in shares of Standard BioTools during the second quarter worth $44,000. 53.74% of the stock is currently owned by institutional investors.

Standard BioTools Stock Performance

Shares of NASDAQ:LAB opened at $2.00 on Friday. The firm has a 50 day simple moving average of $1.87 and a 200 day simple moving average of $1.94. Standard BioTools Inc. has a 52 week low of $1.21 and a 52 week high of $3.04. The company has a market cap of $744.52 million, a PE ratio of -2.82 and a beta of 1.61.

Wall Street Analysts Forecast Growth

Separately, TD Cowen dropped their price target on Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a research note on Thursday, October 31st.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.